APEC1621E NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate)in Patients with Tumors Harboring Activating MAPK Pathway Mutations

NCT03213691

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate)in Patients with Tumors Harboring Activating MAPK Pathway Mutations

Associated Conditions

Multiple Tumor Types

Principal Investigator

Sponsor

Children's Oncology Group

The main goal is to test any good and bad effects of the study drug selumetinib (AZD6244 hydrogen sulfate) on your tumor. A second goal of the study is to evaluate side effects that might be caused by selumetinib (AZD6244 hydrogen sulfate).